DelveInsight’s “Neurodermatitis Market Insights, Epidemiology, and Market Forecast-2032“ report delivers an in-depth understanding of the Neurodermatitis, historical and forecasted epidemiology as well as the Neurodermatitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
The Neurodermatitis market report provides current treatment practices, emerging drugs, Neurodermatitis market share of the individual therapies, and current and forecasted Neurodermatitis market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Neurodermatitis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Neurodermatitis market.
Some of the key facts of Neurodermatitis Market Report:
In 2021, the total cases of Neurodermatitis in the 7MM countries were ~12,000, and these cases are anticipated to increase during the study period. The US accounted for 6,000 cases in 2021
Among the EU4 countries, Germany had the highest number of cases of PNH in 2021, i.e., ~ 1,300 cases, followed by France, which had ~ 900 cases in 2021.
Key Benefits of the Report:
The report covers a descriptive overview of Neurodermatitis, explaining its causes, signs and symptoms, pathophysiology, diagnosis, and currently available therapies
Comprehensive insight has been provided into the Neurodermatitis epidemiology and treatment in the 7MM
Additionally, an all-inclusive account of both the current and emerging therapies for Neurodermatitis is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
A detailed review of the Neurodermatitis market; historical and forecasted is included in the report, covering drug outreach in the 7MM
The report provides an edge while developing business strategies by understanding trends shaping and driving the global Neurodermatitis market
Got queries? Click here to know more about the Neurodermatitis Market Landscape
Neurodermatitis Overview
Neurodermatitis is a rare hematological disorder that results in episodic intravascular hemolysis, hemoglobinuria, hemolysis, and venous thrombosis. PNH is caused by somatic mutations in PIGA in one or more HSC clones. The gene product of PIGA has required for the biosynthesis of glycosylphosphatidylinositol (GPI) anchors; thus, PIGA mutations lead to a deficiency of GPI-anchored proteins, such as complement decay-accelerating factor (also known as CD55) and CD59 glycoprotein (CD59), which are both complement inhibitors. Erythrocytes lacking these proteins are exquisitely sensitive to complement‐mediated intravascular hemolysis. PNH may occur de novo, but it is also associated with aplastic anemia and evolve into aplastic anemia after an indeterminate amount of time.
Neurodermatitis Epidemiology Insights:
In the case of the gender-specific prevalence of PNH, in 2021, females accounted for ~ 3,100 cases as compared to ~ 2,900 cases in males in the United States.
In EU4 and the UK countries, females accounted for more cases than males. In 2019, females accounted for ~ 3,000 cases, whereas males accounted for ~ 2,300 cases.
In the UK, males accounted for ~ 1,100 cases compared to ~ 1,400 cases in females in 2021.
In the case of the gender-specific prevalence of PNH, males accounted for ~ 500 cases as compared to ~ 400 cases in females in Japan in 2021.
Neurodermatitis Epidemiological Segmentation
Neurodermatitis prevalent cases
Neurodermatitis incident cases
Neurodermatitis diagnosed cases
Neurodermatitis treatment cases
Neurodermatitis Market Outlook
The Neurodermatitis market outlook of the report helps to build a detailed comprehension of the historical, current and forecasted Neurodermatitis market trends by analyzing the impact of current Neurodermatitis therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of the Neurodermatitis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Neurodermatitis market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Neurodermatitis market in 7MM is expected to witness a major change in the study period 2019-2032.
Learn more by requesting for sample @ Neurodermatitis Market Landscape
Neurodermatitis Key Companies
Sanofi
Trevi Therapeutics
Galderma
Kiniksa Pharmaceuticals
And many others
Neurodermatitis Therapies
Dupilumab SAR23189
Table of Contents
Key Insights
Report Introduction
Executive Summary of Neurodermatitis Market
Neurodermatitis Disease Background and Overview
Neurodermatitis Epidemiology and patient population
The United States
EU 5
Neurodermatitis Market Emerging Therapies
Neurodermatitis Market Cancer Market Outlook
Market Access and Reimbursement of Therapies
Appendix
Neurodermatitis Market Report Methodology
DelveInsight Capabilities
Disclaimer
About DelveInsight
Click here to read more about Neurodermatitis Market Landscape
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Adya KaulEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/consulting/due-diligence-services